A Phase II Study of TARCEVA (erlotinib) in Combination with Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Feb 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 02 Feb 2018 Planned primary completion date changed from 1 May 2017 to 1 May 2019.
- 25 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.